Boceprevir: New possibilities for the antiviral treatment of chronic hepatitis C
- Authors: Nikitin IG1, Baĭkova IE1, Gogova LM1, Volynkina VM1, Kisliakov VA1
-
Affiliations:
- Issue: Vol 85, No 2 (2013)
- Pages: 76-84
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31231
- ID: 31231
Cite item
Full Text
Abstract
Full Text
Боцепревир: новые возможности противовирусного лечения хронического гепатита С. - Аннотация. В представленном клиническом обзоре освещается проблема современной противовирусной терапии хронического гепатита С. Традиционное противовирусное лечение с использованием пегилированного α-интерферона и рибавирина у пациентов с хроническим гепатитом С, инфицированных вирусом 1-го генотипа, позволяет достичь устойчивого вирусологического ответа (УВО) не более чем у 40% пролеченных пациентов. Внедрение в практику третьего компонента терапии в виде прямых противовирусных агентов, с одной стороны, позволяет существенно повысить УВО, с другой - сократить сроки лечения пациента. В представленном обзоре тщательно проанализированы результаты клинических исследований по препарату боцепревир (прямой противовирусный агент - ингибитор сериновой NS3-протеазы), который при включении в схему противовирусной терапии пегилированными интерферонами и рибавирином существенно улучшает результаты терапии у пациентов с хроническим гепатитом С, инфицированных вирусом 1-го генотипа. Кроме того, обсуждены вопросы безопасности и переносимости препаратов, относящихся к классу ингибиторов сериновой протеазы вируса гепатита С, а также проблема резистентности.About the authors
I G Nikitin
Email: igor.nikitin.64@mail.ru
I E Baĭkova
L M Gogova
V M Volynkina
V A Kisliakov
References
- Tomas D.L. Hepatitis C. Epidemiologic quandaries. Clin Liver Dis 2001; 5 (4): 955-968.
- Verma E.C., Brown R.S. Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10 (4): 919-940.
- Lauer G., Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.
- Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20 (1): 1-16.
- Penin F., Dubuisson J., Rey F.A. et al. Structural biology of hepatitis C virus. Hepatology 2004; 39 (1): 5-19.
- Nielsen S.U., Bassendine M.F., Burt A.D. et al. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004; 85 (Pt 6): 1497-1507.
- Pisarev A.V., Shirokikh N.E., Hellen C.U. Translation initiation by factor-independent binding of eukaryotic ribosomes to internal ribosomal entry sites. C R Biol 2005; 328 (7): 589-605.
- Lee G., Piper D.E., Wang Z. et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J Mol Biol 2006; 357 (4): 1051-1057.
- Biswal В.К., Wang М., Cherney M.M. et al. Non-nucleoside inhibitors binding to hepatitis С virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 2006; 361 (1): 33-45.
- Kunkel M., Lorinczi M., Rijnbrand R. et al. Self-assembly of nudeocapsid-like particles from recombinant hepatitis С virus core protein. J Virol 2001; 75 (5): 2119-2129.
- McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis С infection. N Engl J Med 2009; 361 (6): 580-593.
- Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
- Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection. N Engl J Med 2002; 347 (13): 975-982.
- Sulkowski M. Treatment of hepatitis С in HIV-infected persons: a work in progress. J Hepatol 2008; 48 (1): 5-7.
- Conjeevaram H.S., Fried M.W., Jeffers U. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis С genotype 1. Gastroenterology 2006; 131 (2): 470-477.
- Muir A.J., Bornstein J.D., Killenberg P.G. et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis С in blacks and non-Hispanic whites [see comment] [Erratum appears in N Engl J Med 2004; 351 (12): 1268]. N Engl J Med 2004; 350 (22): 2265-2271.
- Mangia A., Minerva N., Bacca D. et al. Individualized treatment duration for hepatitis С genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47 (1): 43-50.
- Bartenschlager R. Hepatitis С virus replicons: potential role for drug development. Nat Rev Drug Discov 2002; 1 (11): 911-916.
- Llinas-Brunet M., Bailey M.D., Bolger G. et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis С virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004; 47 (7): 1605-168.
- Steinkuhier C., Biasiol G., Brunetti M. et al. Product inhibition of the hepatitis С virus NS3 protease. Biochemistry 1998; 37 (25): 8899-8905.
- Ingallinella P., Altamura S., Bianchi E. et al. Potent peptide inhibitors of human hepatitis С virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998; 37 (25): 8906-8914.
- Lohmann V., KoErner F., Koch J. et al. Replication of subgenomic hepatitis С virus RNAs in a hepatoma cell line. Science 1999; 285 (5424): 110-113.
- Pause A., Kukolj G., Bailey M. et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis С virus RNA. J Biol Chem 2003; 278 (22): 20 374-20 380.
- Hinrichsen H., Benhamou Y., Wedemeyer H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis С virus serine protease inhibitor, in hepatitis С genotype 1 patients. Gastroenterology 2004; 127 (5): 1347-1355.
- Lamarre D., Anderson P.C., Bailey M. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis С virus. Nature 2003; 426 (6963): 186-189.
- Malcolm B.A., Liu R., Lahser F. et al. SCH 503034, a mechanism-based inhibitor of hepatitis С virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50 (3): 1013-1020.
- Sarrazin C., Rouzier R., Wagner F. et al. SCH 503034, a novel hepatitis С virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders [see comment]. Gastroenterology 2007; 132 (4): 1270-1278.
- Sarrazin C., Kieffer T.L., Bartels D. et al. Dynamic hepatitis С virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132 (5): 1767-1777.
- Schiff E., Poordad E., Jacobson I. et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol 2008; 48: S46.
- Kwo P.Y., Lawitz E.J., McCone J. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis С infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376 (9742): 705-716.
- Sulkowski M., Shiffman M.L., Afdhal N.H. et al. Decline in hemoglobin is associated with sustained virologic response (SVR) among HCV genotype 1-infected persons treated with peginterferon (PEG)/ribavirin (RBV): analysis from the ideal study. Gastroenterology 2010; 139: 1602-1611.
- Poordad F., McCone J., Bacon B. et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis С N Engl J Med 2011; 364: 1195-1206.
- Bacon B., Gordon S., Lawitz E. et al. Boceprevir for treatment-resistant chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.